Health Care [ 11/12 ] | Pharmaceuticals [ 49/75 ]
NASDAQ | Common Stock
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.
Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases.
The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.08 Decreased by -148.06% | - |
| May 7, 24 | -0.14 Decreased by -225.55% | - |
| Mar 5, 24 | -0.44 Decreased by -788.20% | - |
| Nov 7, 23 | 0.02 Increased by +166.67% | - |
| Aug 8, 23 | 0.16 Increased by +277.78% | - |
| May 9, 23 | 0.11 Increased by +222.22% | - |
| Mar 7, 23 | -0.05 Increased by +80.77% | - |
| Nov 8, 22 | -0.03 Increased by +57.14% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 9.85 M Decreased by -9.55% | -1.09 M Decreased by -224.47% | Decreased by -11.02% Decreased by -237.61% |
| Mar 31, 24 | 8.50 M Decreased by -7.88% | -1.95 M Decreased by -1.11 K% | Decreased by -22.90% Decreased by -1.20 K% |
| Dec 31, 23 | 9.35 M Increased by +2.51% | -6.29 M Decreased by -155.76% | Decreased by -67.26% Decreased by -149.49% |
| Sep 30, 23 | 10.09 M Decreased by -11.63% | -1.05 M Decreased by -147.93% | Decreased by -10.40% Decreased by -180.55% |
| Jun 30, 23 | 10.89 M Increased by +5.73% | 872.20 K Increased by +163.91% | Increased by +8.01% Increased by +160.45% |
| Mar 31, 23 | 9.22 M Decreased by -17.45% | 192.18 K Increased by +113.70% | Increased by +2.08% Increased by +116.60% |
| Dec 31, 22 | 9.12 M Increased by +9.66% | -2.46 M Increased by +36.07% | Decreased by -26.96% Increased by +41.71% |
| Sep 30, 22 | 11.41 M Increased by +41.38% | -423.23 K Increased by +59.89% | Decreased by -3.71% Increased by +71.63% |